Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
REVENUE:
Grant revenue	$ 257	$ 325
Total revenue	257	325
OPERATING EXPENSES:
Research and development	27,281	17,411
General and administrative	9,755	3,898
Total operating expenses	37,036	21,309
LOSS FROM OPERATIONS	(36,779)	(20,984)
OTHER (EXPENSE) INCOME
Interest income	4	11
Interest expense	(1,073)	(311)
Change in fair value of warrant liabilities	(359)	1
Total other (expense), net	(1,428)	(299)
Net loss attributable to common stockholders	$ (38,207)	$ (21,283)
Net loss per share available to common stockholders-basic and diluted	$ (0.34)	$ (0.22)
Weighted-average common stock outstanding-basic and diluted	113,558,404	96,300,247